Read on Twitter
Caution From 43,998 participants, this Pharma press release was of just 94 participants who received two-doses of their #COVID19 #vaccine and had a blood test 1 month later.
Here is the trial registration https://clinicaltrials.gov/ct2/show/NCT04368728
Before we consider the concept of... https://twitter.com/rtenews/status/1325775444789104640
'effectiveness' Vs a placebo-vaccine, we need to think about whether or not we agree on what outcomes define 'effectiveness'?! e.g. biological immunity from a serology sample Vs development of the disease itself. This debate is outlined here: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30773-8/fulltext
With no less than 24 'primary outcomes' we need to be cautious about what is found.
Another issue is the timeframe- the trial registry acknowledges the need to wait two years from second dose.
Then there's the uncertainy RE side effects, which requires post-trial observation.
Another issue is the timeframe- the trial registry acknowledges the need to wait two years from second dose.
Then there's the uncertainy RE side effects, which requires post-trial observation.
Then there's the cost. And cost-effectiveness (which might be interesting if it requires repeated administration).
After then there's distribution.
Today is neither good news or bad news. It's noise.
Look forward to reading the study,when published, as per the trial registry.
After then there's distribution.
Today is neither good news or bad news. It's noise.
Look forward to reading the study,when published, as per the trial registry.
Just saw this from @nataliexdean (thanks @DrBrendanMcD ) https://twitter.com/nataliexdean/status/1325820512946302977?s=20
